# A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

> **NCT05751486** · PHASE1 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Nasopharyngeal Carcinoma

## Interventions

- **BIOLOGICAL:** Toripalimab injection(subcutaneous)/JS001sc
- **BIOLOGICAL:** Toripalimab injection(subcutaneous)/JS001sc
- **BIOLOGICAL:** Toripalimab /JS001
- **BIOLOGICAL:** Toripalimab injection(subcutaneous)/JS001sc

## Key facts

- **NCT ID:** NCT05751486
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-21
- **Primary completion:** 2023-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751486, "A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05751486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*